Slingshot members are tracking this corporate initiative:
Lexicon Pharma (LXRX) Acquires Exclusive Research Rights from Bristol-Myers Squibb (BMY) for Neuropathic Pain Candidate LX9211
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Nov 07, 2016 Projected Implementation: Q4, 2016 Relevance Tracked Until: Q4, 2018
Don’t see a project related to the strategic initiative you care about?
Related Keywords Exclusive Research Rights, Neuropathic Pain, Lx9211